Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dean F. Bajorin, Padmanee Sharma, Seth P. Lerner, Robert Brownell Sims, Amanda Sanders, Todd DeVries, Nadeem A. Sheikh, Leonard G. Gomella
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2998772549